On December 15, 2025, during the book-building process for Artgen Biotech's bonds, investor demand exceeded the initial offering volume by more than five times.
According to Dmitry Krasotkin, IR Director of Artgen Biotech: "The fivefold oversubscription reflects market confidence in the Company. Investors showed exceptionally high interest in the issue, actively competing for the opportunity to become creditors of the Company. The extraordinary demand clearly demonstrated the appeal of Artgen Biotech's bonds among the financial community."
Due to the oversubscription, the coupon rate had to be revised downward from 23% to 21%. Furthermore, to balance supply and demand, investor orders were reduced on a pro-rata basis. The final volume of satisfied orders, in accordance with the previously approved and published issuance documents, amounted to RUB 300 million.
The technical placement of the non-convertible uncertificated bonds of series BO-02 with a maturity of 5 years is scheduled for December 23, 2025. A total of 300,000 bonds with a par value of RUB 1,000 per bond will be issued.
Earlier, Sergey Masyuk, Director of Artgen Biotech, noted that "the Company is raising a bond loan to stably improve the Group's liquidity in the medium term, in order to ensure dynamic development and advance our R&D efforts toward practical healthcare, as well as to support ongoing operating and financial activities. Artgen Biotech has a strong financial position and a solid, high credit rating. The Company's financial indicators allow it to raise additional funds without a long-term downgrade of its rating or loss of financial stability. Artgen Biotech is actively driving new projects forward. The Company's ecosystem includes around 30 early-stage R&D projects, from which up to 10 gene therapy drug candidates are expected to emerge for the treatment of genetic, age-related, infectious, and oncological diseases. Furthermore, we are progressing already registered R&D projects and products at advanced stages that are close to receiving marketing authorization."
Artgen Biotech is a biotechnology company with a portfolio of innovative platform R&D projects, bringing them into practical healthcare. The Artgen Biotech Group comprises companies at various stages of development — from the seed stage to early growth and maturity — as well as companies that form an ecosystem for accelerating biotech R&D within the Group.